References
- Brandt T, Dichgans J, Diener HC, editors. Therapie und Verlauf neurologischer Erkrankungen. Stuttgart: Verlag W. Kohlhammer, 2003.
- Kovacs SO, Kovacs SC. Dermatomyositis. J Am Acad Dermatol 1998;39:899 — 920.
- Aragones JM, Bolibar I, Bonfill X, Bufill E, Mummany A, Alonso F, et al. Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 2003;60:1024–6.
- Wirtz PW, Nijnuis MG, Sotodeh M, Willems LN, Brahim JJ, Putter H, et al. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol 2003;250:698–701.
- Drachman DB. Myasthenia gravis. N Engl J Med 1994;330:1797–810.
- Hachulla E. Dermatomyositis and polymyositis: clinical aspects and treatment. Ann Med Interne (Paris) 2001;152:455–64.
- McEvoy KM. Diagnosis and treatment of Lambert-Eaton myasthenic syndrome. Neurol Clin 1994;12:387–99.
- Ferrer I. Pathology of paraneoplastic syndromes of the central and peripheral nervous systems and muscle. Rev Neurol 2000;31:1228 — 36.
- Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 2001;85:41–5.
- Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96–100.
- Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcho-line receptor antibodies. Nat Med 2001;7:365–8.
- Vincent A, McConville J, Farrugia ME, Bowen J, Plested P, Tang T, et al. Antibodies in myasthenia gravis and related disorders. Ann N Y Acad Sci 2003;998:324–35.
- Artigou C, Guerin JM, Wallach D, Beillevaire T, Aubiniere E, Cottenot F. Dermatomyositis and Lambert-Eaton syndrome. Association of 2 paraneoplastic muscular syndromes. Ann Dermatol Venereol 1982;109:737–8.
- Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344–7.
- Tim RW, Sanders DB. Repetitive nerve stimulation studies in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1994;17:995–1001.
- Sanders DB, Massey JM, Sanders LL, Edwards U. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000;54:603–7.
- Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome (Cochrane Review). Cochrane Database Syst Rev 2003;CD003279.
- Raschilas F, Mouthon L, Andre MH, Azorin J, Couvelard A, Guillevin L. Concomitant polymyositis and myasthenia gravis reveal malignant thymoma. A case report and review of the literature. Ann Med Interne (Paris) 1999;150:370–3.
- Behan WM, Behan PO, Doyle D. Association of myasthenia gravis and polymyositis with neoplasia, infection and autoimmune disorders. Acta Neuropathol (Berlin) 1982;57: 221–9.
- Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 1997;147:35–42.
- Chan LS, Soong HK, Foster CS, Hammerberg C, Cooper KD. Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome. J Am Med Assoc 1991;266: 1543–6.
- Lapiere JC, Woodley DT, Parente MG, Iwasaki T, Wynn KC, Christiano AM, et al. Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa. J Clin Invest 1993;92:1831–9.
- Paige DG, Leonard JN, Wojnarowska F, Fry L. Linear IgA disease and ulcerative colitis. Br J Dermatol 1997;136: 779–82.
- Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, Zone JJ, Black MM, et al. Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol 1998;110: 103–9.